In this episode, Drs. Erin Michos and Steven Nissen discuss newly emerging therapies for elevated Lp(a) management and forthcoming developments in research. Drs. Michos and Nissen highlight the key differences between therapies in late trial stages and discuss upcoming cardiovascular outcome trials.

This CardiaCast episode is part of an ACC course titled Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap. Educational grant support is provided by Novartis. To visit the Online Course page for the Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap Grant, click here!

Suggested Materials:

1. Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): actionable strategies for risk assessment and mitigation. Am J Prev Cardiol. 2024;18:100651.

1. Tsimikas S, Fazio S, Ferdinand KC, et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018;71:177-92.

1. Reyes-Soffer G, Ginsberg HN, Berglund L, et al; on behalf of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. ArteriosclerThromband Vasc Biol 2022;42:e48-e60.

1. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol 2024;18:e308-e319.

Subscribe to CardiaCast | More information on Elevating Lp(a) HERE